REG - GlaxoSmithKline PLC - Director/PDMR Shareholding <Origin Href="QuoteRef">GSK.L</Origin> - Part 1

GSKAnnouncement

16/10/2017 16:55

RNS Number : 7388T
GlaxoSmithKline PLC
16 October 2017
GlaxoSmithKline plc(the'Company')
Transaction notification
1.
Details of PDMR/person closely associated with them ('PCA')
a)
Name
Ms E Walmsley
b)
Position/status
Chief Executive Officer
c)
Initial notification/
amendment
Initial notification
2. 
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)
Name 
GlaxoSmithKline plc
b)
LEI
5493000HZTVUYLO1D793
3.
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted
a)
Descriptionofthefinancial instrument
Ordinary shares of 25 pence each ('Ordinary Shares')
ISIN: GB0009252882 
b)
Natureofthetransaction
Increase in notional interest in Ordinary Shares following the re-investment of dividends paid to shareholders on 12 October 2017 on Ordinary Shares held in the Company's 2009 Deferred Annual Bonus Plan.
c)
Price(s)and volume(s)
Price(s)
Volume(s)
15.275
75.595 (personal contribution)
15.275
187.204 (personal contribution)
15.275
203.821 (personal contribution)
15.275
75.595 (personal contribution)
15.275
187.191 (personal contribution)
15.275
203.809 (personal contribution)
15.275
75.595 (matching shares)
15.275
187.204 (matching shares)
15.275
203.821 (matching shares)
15.275
75.595 (matching shares)
15.275
187.191 (matching shares)
15.275
203.809 (matching shares)
d)
Aggregatedinformation
AggregatedvolumePrice
1,866.43
15.275
e)
Date ofthetransaction
2017-10-12
f)
Placeofthe transaction
n/a
1.
Details of PDMR/person closely associated with them ('PCA')
a)
Name
Mr R G Connor
b)
Position/status
President, Global Manufacturing & Supply
c)
Initial notification/
amendment
Initial notification
2. 
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)
Name 
GlaxoSmithKline plc
b)
LEI
5493000HZTVUYLO1D793
3.
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted
a)
Descriptionofthefinancial instrument
Ordinary shares of 25 pence each ('Ordinary Shares')
ISIN: GB0009252882 
b)
Natureofthetransaction
Increase in notional interest in Ordinary Shares following the re-investment of dividends paid to shareholders on 12 October 2017 on Ordinary Shares held in the Company's 2009 Deferred Annual Bonus Plan.
c)
Price(s)and volume(s)
Price(s)
Volume(s)
15.275
55.361 (personal contribution)
15.275
127.190 (personal contribution)
15.275
106.128 (personal contribution)
15.275
55.361 (personal contribution)
15.275
106.115 (personal contribution)
15.275
55.361 (matching shares)
15.275
127.19 (matching shares)
15.275
106.128 (matching shares)
15.275
55.361 (matching shares)
15.275
106.115 (matching contribution)
d)
Aggregatedinformation
AggregatedvolumePrice
900.310
15.275
e)
Date ofthetransaction
2017-10-12
f)
Placeofthe transaction
n/a
1.
Details of PDMR/person closely associated with them ('PCA')
a)
Name
Mr L Debruyne
b)
Position/status
President, Global Vaccines
c)
Initial notification/
amendment
Initial notification
2. 
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)
Name 
GlaxoSmithKline plc
b)
LEI
5493000HZTVUYLO1D793
3.
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted
a)
Descriptionofthefinancial instrument
Ordinary shares of 25 pence each ('Ordinary Shares')
ISIN: GB0009252882 
b)
Natureofthetransaction
Increase in notional interest in Ordinary Shares following the re-investment of dividends paid to shareholders on 12 October2017 on Ordinary Shares held in the Company's 2009 Deferred Annual Bonus Plan.
c)
Price(s)and volume(s)
Price(s)
Volume(s)
15.275
178.377 (personal contribution)
15.275
178.365 (personal contribution)
15.275
178.377 (matching shares)
15.275
178.365 (matching shares)
d)
Aggregatedinformation
AggregatedvolumePrice
713.484
15.275
e)
Date ofthetransaction
2017-10-12
f)
Placeofthe transaction
n/a
1.
Details of PDMR/person closely associated with them ('PCA')
a)
Name
Mr S Dingemans
b)
Position/status
Chief Financial Officer
c)
Initial notification/
amendment
Initial notification
2. 
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)
Name 
GlaxoSmithKline plc
b)
LEI
5493000HZTVUYLO1D793
3.
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted
a)
Descriptionofthefinancial instrument
Ordinary shares of 25 pence each ('Ordinary Shares')
ISIN: GB0009252882 
b)
Natureofthetransaction
Increase in notional interest in Ordinary Shares following the re-investment of dividends paid to shareholders on 12 October 2017 on Ordinary Shares held in the Company's 2009 Deferred Annual Bonus Plan.
c)
Price(s)and volume(s)
Price(s)
Volume(s)
15.275
105.590 (personal contribution)
15.275
247.218 (personal contribution)
15.275
185.166 (personal contribution)
15.275
105.576 (personal contribution)
15.275
247.205 (personal contribution)
15.275
185.166 (personal contribution)
15.275
105.590 (matching shares)
15.275
247.218 (matching shares)
15.275
185.166 (matching shares)
15.275
105.576 (matching shares)
15.275
247.205 (matching shares)
15.275
185.166 (matching shares)
d)
Aggregatedinformation
AggregatedvolumePrice
2,151.842
15.275
e)
Date ofthetransaction
2017-10-12
f)
Placeofthe transaction
n/a
1.
Details of PDMR/person closely associated with them ('PCA')
a)
Name
Mr N Hirons
b)
Position/status
SVP, Global Ethics & Compliance
c)
Initial notification/
amendment
Initial notification
2. 
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)
Name 
GlaxoSmithKline plc
b)
LEI
5493000HZTVUYLO1D793
3.
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted
a)
Descriptionofthefinancial instrument
Ordinary shares of 25 pence each ('Ordinary Shares')
ISIN: GB0009252882 
b)
Natureofthetransaction
Increase in notional interest in Ordinary Shares following the re-investment of dividends paid to shareholders on 12 October2017 on Ordinary Shares held in the Company's 2009 Deferred Annual Bonus Plan.
c)
Price(s)and volume(s)
Price(s)
Volume(s)
15.275
38.762 (personal contribution)
15.275
91.407 (personal contribution)
15.275
67.081 (personal contribution)
15.275
38.762 (personal contribution)
15.275
91.407 (personal contribution)
15.275
67.068 (personal contribution)
15.275
38.762 (matching shares)
15.275
91.407 (matching shares)
15.275
67.081 (matching shares)
15.275
38.762 (matching shares)
15.275
91.407 (matching shares)
15.275
67.068 (matching shares)
d)
Aggregatedinformation
AggregatedvolumePrice
788.974
15.275
e)
Date ofthetransaction
2017-10-12
f)
Placeofthe transaction
n/a
1.
Details of PDMR/person closely associated with them ('PCA')
a)
Name
Mr B McNamara
b)
Position/status
CEO, GSK Consumer Healthcare
c)
Initial notification/
amendment
Initial notification
2. 
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)
Name 
GlaxoSmithKline plc
b)
LEI
5493000HZTVUYLO1D793
3.
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted
a)
Descriptionofthefinancial instrument
American Depositary Shares ('ADSs')
ISIN: US37733W1053 
b)
Natureofthetransaction
Increase in notional interest in ADSs following the re-investment of dividends paid to shareholders on 12 October 2017 on ADSs held in the Company's 2009 Deferred Annual Bonus Plan.
c)
Price(s)and volume(s)
Price(s)
Volume(s)
$41.020
75.963 (personal contribution)
$41.020
75.963 (matching shares)
d)
Aggregatedinformation
AggregatedvolumePrice
151.926
$41.020
e)
Date ofthetransaction
2017-10-12
f)
Placeofthe transaction
n/a
1.
Details of PDMR/person closely associated with them ('PCA')
a)
Name
Mr D S Redfern
b)
Position/status
Chief Strategy Officer
c)
Initial notification/
amendment
Initial notification
2. 
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)
Name 
GlaxoSmithKline plc
b)
LEI
5493000HZTVUYLO1D793
3.
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted
a)
Descriptionofthefinancial instrument
Ordinary shares of 25 pence each ('Ordinary Shares')
ISIN: GB0009252882 
b)
Natureofthetransaction
Increase in notional interest in Ordinary Shares following the re-investment of dividends paid to shareholders on 12 October 2017 on Ordinary Shares held in the Company's 2009 Deferred Annual Bonus Plan.
c)
Price(s)and volume(s)
Price(s)
Volume(s)
15.275
62.115 (personal contribution)
15.275
116.331 (personal contribution)
15.275
84.422 (personal contribution)
15.275
62.115 (personal contribution)
15.275
116.331 (personal contribution)
15.275
84.409 (personal contribution)
15.275
62.115 (matching shares)
15.275
116.331 (matching shares)
15.275
84.422 (matching shares)
15.275
62.115 (matching shares)
15.275
116.331 (matching shares)
15.275
84.409 (matching shares)
d)
Aggregatedinformation
AggregatedvolumePrice
1,051.446
15.275
e)
Date ofthetransaction
2017-10-12
f)
Placeofthe transaction
n/a
1.
Details of PDMR/person closely associated with them ('PCA')
a)
Name
Ms C Thomas
b)
Position/status
SVP, Human Resources
c)
Initial notification/
amendment
Initial notification
2. 
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)
Name 
GlaxoSmithKline plc
b)
LEI
5493000HZTVUYLO1D793
3.
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted
a)
Descriptionofthefinancial instrument
Ordinary shares of 25 pence each ('Ordinary Shares')
ISIN: GB0009252882 
b)
Natureofthetransaction
Increase in notional interest in Ordinary Shares following the re-investment of dividends paid to shareholders on 12 October 2017 on Ordinary Shares held in the Company's 2009 Deferred Annual Bonus Plan.
c)
Price(s)and volume(s)
Price(s)
Volume(s)
15.275
83.607 (personal contribution)
15.275
170.189 (personal contribution)
15.275
127.067 (personal contribution)
15.275
83.594 (personal contribution)
15.275
170.189 (personal contribution)
15.275
127.067 (personal contribution)
15.275
83.607 (matching shares)
15.275
170.189 (matching shares)
15.275
127.067 (matching shares)
15.275
83.594 (matching shares)
15.275
170.189 (matching shares)
15.275
127.067 (matching shares)
d)
Aggregatedinformation
AggregatedvolumePrice
1,523.426
15.275
e)
Date ofthetransaction
2017-10-12
f)
Placeofthe transaction
n/a
1.
Details of PDMR/person closely associated with them ('PCA')
a)
Name
Mr P C Thomson
b)
Position/status
President, Global Affairs
c)
Initial notification/
amendment
Initial notification
2. 
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)
Name 
GlaxoSmithKline plc
b)
LEI
5493000HZTVUYLO1D793
3.
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted
a)
Descriptionofthefinancial instrument
Ordinary shares of 25 pence each ('Ordinary Shares')
ISIN: GB0009252882 
b)
Natureofthetransaction
Increase in notional interest in Ordinary Shares following the re-investment of dividends paid to shareholders on 12 October 2017 on Ordinary Shares held in the Company's 2009 Deferred Annual Bonus Plan.
c)
Price(s)and volume(s)
Price(s)
Volume(s)
15.275
56.787 (personal contribution)
15.275
104.127 (personal contribution)
15.275
79.994 (personal contribution)
15.275
56.787 (matching shares)
15.275
104.127 (matching shares)
15.275
79.994 (matching shares)
d)
Aggregatedinformation
AggregatedvolumePrice
481.816
15.275
e)
Date ofthetransaction
2017-10-12
f)
Placeofthe transaction
n/a
1.
Details of PDMR/person closely associated with them ('PCA')
a)
Name
Mr D E Troy
b)
Position/status
SVP & General Counsel
c)
Initial notification/
amendment
Initial notification
2. 
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)
Name 
GlaxoSmithKline plc
b)
LEI
5493000HZTVUYLO1D793
3.
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted
a)
Descriptionofthefinancial instrument
American Depositary Shares ('ADSs')
ISIN: US37733W1053
b)
Natureofthetransaction
Increase in notional interest in ADSs following the re-investment of dividends paid to shareholders on 12 October 2017 on ADSs held in the Company's 2009 Deferred Annual Bonus Plan.
c)
Price(s)and volume(s)
Price(s)
Volume(s)
$41.020
43.227 (personal contribution)
$41.020
97.329 (personal contribution)
$41.020
80.611 (personal contribution)
$41.020
43.227 (personal contribution)
$41.020
97.329 (personal contribution)
$41.020
80.599 (personal contribution)
$41.020
43.227 (matching shares)
$41.020
97.329 (matching shares)
$41.020
80.611 (matching shares)
$41.020
43.227 (matching shares)
$41.020
97.329 (matching shares)
$41.020
80.599 (matching shares)
d)
Aggregatedinformation
AggregatedvolumePrice
884.644
$41.020
e)
Date ofthetransaction
2017-10-12
f)
Placeofthe transaction
n/a
1.
Details of PDMR/person closely associated with them ('PCA')
a)
Name
Dr P J T Vallance
b)
Position/status
President, R&D
c)
Initial notification/
amendment
Initial notification
2. 
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)
Name 
GlaxoSmithKline plc
b)
LEI
5493000HZTVUYLO1D793
3.
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted
a)
Descriptionofthefinancial instrument
Ordinary shares of 25 pence each ('Ordinary Shares')
ISIN: GB0009252882 
b)
Natureofthetransaction
Increase in notional interest in Ordinary Shares following the re-investment of dividends paid to shareholders on 12 October 2017 on Ordinary Shares held in the Company's 2009 Deferred Annual Bonus Plan.
c)
Price(s)and volume(s)
Price(s)
Volume(s)
15.275
123.070 (personal contribution)
15.275
200.197 (personal contribution)
15.275
138.016 (personal contribution)
15.275
123.070 (personal contribution)
15.275
200.197 (personal contribution)
15.275
138.016 (personal contribution)
15.275
123.070 (matching shares)
15.275
200.197 (matching shares)
15.275
138.016 (matching shares)
15.275
123.070 (matching shares)
15.275
200.197 (matching shares)
15.275
138.016 (matching shares)
d)
Aggregatedinformation
AggregatedvolumePrice
1,845.132
15.275
e)
Date ofthetransaction
2017-10-12
f)
Placeofthe transaction
n/a

This information is provided by RNS
The company news service from the London Stock Exchange
  END
DSHEQLFFDBFEFBF